Announced Date: 2025-09-17 (September 17, 2025)
Asset Name: 2MW7141
Licensor (Seller): Mabwell Bio (China)
Licensee (Buyer): Kalexo Bio (US) <by Aditum Bio Fund 3, L.P. >
.
Asset Modality: SiRNA
Asset Target: undisclosed
Potential Indication: Management of dyslipidaemias
Current Stage: preclinical
.
Scope of Authority:
Mabwell will grant Kalexo Bio the exclusive global rights to develop, manufacture, and commercialize 2MW7141.
.
Payment Detail:
Mabwell will receive an upfront payment and near term payment of $120 million，
Mabwell may receive equity of Kalexo Bio.
Eligible to receive potential milestone payment up to $1 billion.
.
Link:
.
Note:
Chinese Name of Mabwell 迈威生物
